ProMIS Neurosciences Announces Second Quarter 2021 Results
12 août 2021 07h30 HE
|
ProMIS Neurosciences Inc.
TORONTO and CAMBRIDGE, Mass., Aug. 12, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS or the Company”), a biotechnology company focused on the discovery and...
ProMIS Neurosciences Issues Chairman’s Memorandum
04 août 2021 07h30 HE
|
ProMIS Neurosciences Inc.
TORONTO and CAMBRIDGE, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
ProMIS Neurosciences to Present at 2021 Alzheimer’s Association International Conference
22 juil. 2021 07h15 HE
|
ProMIS Neurosciences Inc.
TORONTO and CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
ProMIS Neurosciences Obtains Receipt for Final Base Shelf Prospectus
08 juil. 2021 07h30 HE
|
ProMIS Neurosciences Inc.
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES TORONTO and...
ProMIS Neurosciences Announces Results of Annual Meeting of Shareholders
02 juil. 2021 07h30 HE
|
ProMIS Neurosciences Inc.
TORONTO and CAMBRIDGE, Mass., July 02, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
ProMIS Neurosciences congratulates Biogen on FDA accelerated approval of aducanumab for Alzheimer’s disease
08 juin 2021 07h30 HE
|
ProMIS Neurosciences Inc.
TORONTO and CAMBRIDGE, Mass., June 08, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
ProMIS Neurosciences Files Preliminary Short Form Base Shelf Prospectus
03 juin 2021 07h30 HE
|
ProMIS Neurosciences Inc.
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES TORONTO and...
ProMIS Neurosciences appoints renowned scientist, Dr. David Wishart as Chief Physics Officer
27 mai 2021 07h30 HE
|
ProMIS Neurosciences Inc.
TORONTO, and CAMBRIDGE, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
ProMIS Neurosciences initiates commercialization of COVID-19 serology assay
25 mai 2021 07h30 HE
|
ProMIS Neurosciences Inc.
TORONTO and CAMBRIDGE, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...
ProMIS Neurosciences re-initiates path to IND for PMN310 with producer cell line development
21 mai 2021 08h30 HE
|
ProMIS Neurosciences Inc.
TORONTO and CAMBRIDGE, Mass., May 21, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody...